Answers are grounded in this paper and cite their sources.
The potential clinical benefit and impact on tolerability of combining androgen receptor pathway inhibitors (ARPIs) with [177Lu]Lu-PSMA-617 remain uncertain and were not evaluated in the primary analysis of VISION (NCT03511664). In this secondary analysis, we assessed efficacy and safety of [177Lu]Lu-PSMA-617 with and without concomitant ARPIs in previously treated patients (≥1 ARPI and 1 or 2 taxanes) with metastatic androgen pathway modulator–resistant prostate cancer (formerly metastatic castration-resistant prostate cancer). Methods: Prostate-specific antigen (PSA) response, duration of PSA response, PSA progression-free survival (PSA-PFS), radiographic progression-free survival, overall survival (OS), and adverse events were explored in this post hoc analysis. For OS, a time-adjusted multivariate analysis was performed to control for biases. Results: Among patients randomized to [177Lu]Lu-PSMA-617, 289 versus 262 in the full analysis set and 283 versus 246 patients in the safety analysis set received treatment with and without concomitant ARPIs, respectively. Among patients treated with versus without ARPIs, 49.7% versus 42.2% had a PSA response (≥50% reduction in PSA level) (odds ratio, 1.41; 95% CI, 0.93–2.13; nominal 2-sided P = 0.103), with a median response duration of 9.4 mo versus 8.8 mo, respectively. The median PSA-PFS was 8.6 mo versus 7.3 mo (hazard ratio, 0.87; 95% CI, 0.70–1.09; P = 0.120 [nominal 1-sided stratified log-rank test]). A time-adjusted multivariate analysis showed a median OS of 16.6 versus 13.3 mo (hazard ratio, 0.79; 95% CI, 0.56–1.10; 2-sided P = 0.160). The frequency, nature, and severity of adverse events were similar between groups. Conclusion: The clinical benefits of [177Lu]Lu-PSMA-617 were similar with and without concomitant ARPIs. The addition of concomitant ARPIs to [177Lu]Lu-PSMA-617 provided a numerically higher PSA response and a numerically greater median PSA-PFS and median OS.
No takes yet. Share an insight, caveat, or question.
Yazdanpanah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: